Inhibition of a broad range of SARS-CoV-2 variants by antiviral phytochemicals in hACE2 mice

Antiviral Res. 2022 Aug:204:105371. doi: 10.1016/j.antiviral.2022.105371. Epub 2022 Jun 28.

Abstract

Although several vaccines and antiviral drugs against SARS-CoV-2 are currently available, control and prevention of COVID-19 through these interventions is limited due to inaccessibility and economic issues in some regions and countries. Moreover, incomplete viral clearance by ineffective therapeutics may lead to rapid genetic evolution, resulting in the emergence of new SARS-CoV-2 variants that may escape the host immune system as well as currently available COVID-19 vaccines. Here, we report that phytochemicals extracted from Chlorella spp. and Psidium guajava possess broad-spectrum antiviral activity against a range of SARS-CoV-2 variants. Through chromatography-based screening, we identified four bioactive compounds and subsequently demonstrated their potential antiviral activities in vivo. Interestingly, in hACE2 mice, treatment with these compounds significantly attenuates SARS-CoV-2-induced proinflammatory responses, demonstrating their potential anti-inflammatory activity. Collectively, our study suggests that phytochemicals from edible plants may be readily available therapeutics and prophylactics against multiple SARS-CoV-2 strains and variants.

Keywords: Antiviral therapy; Chlorella; Guava; Prophylactics; SARS-CoV-2; Variants.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use
  • COVID-19 Drug Treatment*
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Chlorella*
  • Humans
  • Mice
  • Phytochemicals / pharmacology
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • COVID-19 Vaccines
  • Phytochemicals

Supplementary concepts

  • SARS-CoV-2 variants